Abbott Said to Agree to Pay $1.3 Billion for Depakote Suits

Abbott Laboratories agreed to pay at least $1.3 billion to settle claims by the U.S. government and 24 states alleging the company illegally marketed its Depakote epilepsy drug, people familiar with the accords said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.